Comparison of Tenofovir Alafenamide and Entecavir Therapy in Patients with Chronic Hepatitis B Initially Treated with Tenofovir Disoproxil: A Retrospective Observational Survey

Basit Öğe Kaydı
dc.authoridtoplu, sibel altunışık/0000-0002-2915-4666
dc.authoridmete, ayşe özlem/0000-0003-0994-4465
dc.authoridÖren, Meryem Merve/0000-0002-3383-7830;
dc.authorwosidtoplu, sibel altunışık/ABH-5816-2020
dc.authorwosidmete, ayşe özlem/AAA-5072-2021
dc.authorwosidAkgul, Fethiye/GYU-0934-2022
dc.authorwosidKarasahin, Omer/JBJ-0597-2023
dc.authorwosidyıldız, yeşim/AAD-2219-2022
dc.authorwosidÖren, Meryem Merve/AAD-1806-2020
dc.authorwosidKömür, Süheyla/E-9639-2018
dc.contributor.authorKalkan, Irem Akdemir
dc.contributor.authorKarasahin, Omer
dc.contributor.authorSarigul, Figen
dc.contributor.authorToplu, Sibel Altunisik
dc.contributor.authorAladag, Murat
dc.contributor.authorAkgul, Fethiye
dc.contributor.authorMete, Ayse Ozlem
dc.date.accessioned2024-08-04T20:51:48Z
dc.date.available2024-08-04T20:51:48Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: In chronic hepatitis B patients with or exposed to the risk of osteoporosis or renal dysfunction, switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide fumarate (TAF) or entecavir (ETV) maybe the right choice. Objectives: This study aimed to present real-life data in terms of the efficacy and safety of a TAF/ETV treatment change while receiving TDF. Methods: This retrospective study was conducted on 344 adult patients from 10 centers. The data of patients who had changed to ETV (n = 107) and TAF (n = 237) while receiving TDF were analyzed. The data collected at 0 and 6 months of treatment were analyzed. The virological response was assessed based on undetected hepatitis B virus (HBV) DNA. Serum alanine aminotransferase (ALT) values were used to evaluate the biochemical response. For renal function, serum creatinine and phosphorus, as well as estimated glomerular filtration rate (eGFR), were recorded. Moreover, lumbar spine and hip T-scores along with the serum lipid profile were evaluated. Results: The mean age of patients was 41.14 +/- 13.46 years, and 224 (65.1%) of the participants were male. The treatment arms were not significantly different in terms of demographic characteristics, comorbid diseases, infection duration, family history of HBV infection, blood platelet count, serum biomarkers, such as ALT, phosphorus, creatinine, total bilirubin, albumin, lipid profile, and HBV DNA levels at the beginning. No statistically significant difference was found between the proportion of undetectable HBV DNA of the two treatment groups after 6 months (P = 0.221). The ALT normalization in the ETV and TAF groups at the sixth month compared to the baseline levels was not significantly different (P = 0.853, P = 0.330, respectively). There was no statistically significant difference between the two treatment arms regarding changes in eGFR, creatinine, phosphorus, hip, and spine T-scores from baseline to 6 months (P = 0.296, P = 0.78, P = 0.141, P = 0.832, P = 0.947, respectively). In those who switched to TAF or ETV, low-density lipoproteins cholesterol were observed to be significantly higher after 6 months compared to baseline values (P = 0.002, P = 0.049, respectively). The TC increased significantly in the TAF group (P = 0.035). Conclusions: Our study showed that switching to ETV and TAF sustained the viral suppression and biochemical response achieved by TDF therapy. The treatment switch to TAF of ETV can control renal dysfunction and reduce bone mineral density caused by TDF.en_US
dc.identifier.doi10.5812/hepatmon.118721
dc.identifier.issn1735-143X
dc.identifier.issn1735-3408
dc.identifier.issue10en_US
dc.identifier.scopus2-s2.0-85127217552en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.urihttps://doi.org/10.5812/hepatmon.118721
dc.identifier.urihttps://hdl.handle.net/11616/100566
dc.identifier.volume21en_US
dc.identifier.wosWOS:000766814300002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBrieflanden_US
dc.relation.ispartofHepatitis Monthlyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEntecaviren_US
dc.subjectHepatitis Ben_US
dc.subjectTenofovir Disoproxilen_US
dc.subjectTenofovir Alafenamideen_US
dc.titleComparison of Tenofovir Alafenamide and Entecavir Therapy in Patients with Chronic Hepatitis B Initially Treated with Tenofovir Disoproxil: A Retrospective Observational Surveyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu